Home › Companies › VERONA PHARMA PLC › 2023-2024

VERONA PHARMA PLC 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and VERONA PHARMA PLC’s Form 8-K, filed 2024-04-30 (Item 5.07 on EDGAR). Page generated 02 October 2026.

16Reported items
127Asset managers
980Fund votes
2024-04-26Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VERONA PHARMA PLC in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VERONA PHARMA PLC

These tallies are VERONA PHARMA PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-04-30 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VERONA PHARMA PLC — official shareholder meeting results, meeting held 2024-04-26
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 2. To re-elect Martin Edwards as a Director of the Company.	617,654,873	309,040	--	777,838	--	Majority: yes
Proposal 3. To re-elect Sven Anders Ullman as a Director of the Company.	590,081,657	27,882,176	--	777,918	--	Majority: yes
Proposal 4. To re-elect Christina Ackerman as a Director of the Company.	617,786,657	169,976	--	785,118	--	Majority: yes
Proposal 5. To re-elect Michael Austwick as a Director of the Company.	617,807,153	170,296	--	764,302	--	Majority: yes
Proposal 6. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2023 and the report of the auditors thereon (the "2023 U.K. Annual Report").	616,905,143	1,179,344	--	657,264	--	Majority: yes
Proposal 10. To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.	603,137,815	195,320	--	15,408,616	--	Majority: yes
Proposal 11. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024.	618,024,719	65,608	--	651,424	--	Majority: yes
Proposal 12. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.	594,069,521	23,464,550	--	1,207,680	--	Majority: yes

Source: VERONA PHARMA PLC, Form 8-K, filed with the SEC on 2024-04-30 — read the filing on EDGAR.

How asset managers voted at the VERONA PHARMA PLC 2023-2024 meeting

Each item below shows how the 127 asset managers that disclosed a VERONA PHARMA PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VERONA PHARMA PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 594,069,521AGAINST: 23,464,550

VERONA PHARMA PLC’s own tally for this item (“Proposal 12. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”): 594,069,521 for, 23,464,550 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 92% for, 4% against (95% of the company cast a for/against vote).

The 125 asset managers below cast 93% of the shares they voted on this item FOR (47,636,258 for, 3,388,630 against).

FOR 93%

FOR: 47,636,258 (93.4%)AGAINST: 3,388,630 (6.6%)ABSTAIN: 177 (0.0%)NOT VOTED: 2,904 (0.0%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
RA CAPITAL MANAGEMENT, L.P.	6,214,670	0	For
Fidelity	3,979,839	0	For
Vivo Capital, LLC	3,610,108	0	For
ORBIMED ADVISORS LLC	3,444,363	0	For
Wellington	3,303,090	0	For
Deep Track Capital, LP	3,187,415	0	For
PERCEPTIVE ADVISORS LLC	2,936,957	0	For
Carlyle Group Inc.	2,457,500	0	For
MUTUAL FUND SERIES TRUST	2,243,520	0	For
Federated Hermes	2,087,728	0	For
MAVERICK CAPITAL LTD	1,375,557	0	For
Vanguard	1,304,406	0	For
JENNISON ASSOCIATES LLC	0	1,229,810	Against
Janus Henderson	1,139,534	0	For
Caligan Partners LP	1,049,216	0	For
Octagon Capital Advisors LP	1,027,468	0	For
American Century	991,721	0	For
Ally Bridge Group (NY) LLC	783,083	0	For
Woodline Partners LP	752,980	0	For
Laurion Capital Management LP	703,885	0	For
Prudential/PGIM	0	541,647	Against
Hood River Capital Management LLC	0	506,798	Against
JANUS INVESTMENT FUND	492,127	0	For
Hartford	485,679	0	For
Affinity Asset Advisors, LLC	412,995	0	For

Showing the 25 largest of 125 asset managers. See all 125 in the interactive database.

2. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended 31 December 2023

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

91% fund support · no official result

FOR 91%9%

The 68 asset managers below cast 91% of the shares they voted on this item FOR (15,483,994 for, 1,541,693 against).

FOR: 15,483,994 (90.9%)AGAINST: 1,541,693 (9.1%)ABSTAIN: 177 (0.0%)

Largest asset managers voting on “To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Repor” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Deep Track Capital, LP	3,187,415	0	For
MUTUAL FUND SERIES TRUST	2,243,520	0	For
Fidelity	1,724,583	0	For
MAVERICK CAPITAL LTD	1,375,557	0	For
Vanguard	1,304,406	0	For
Federated Hermes	1,043,864	0	For
ORBIMED ADVISORS LLC	916,981	0	For
Prudential/PGIM	0	541,647	Against
Hood River Capital Management LLC	0	506,798	Against
JANUS INVESTMENT FUND	492,127	0	For
American Century	487,463	0	For
Hartford	485,679	0	For
Affinity Asset Advisors, LLC	412,995	0	For
BOOTHBAY FUND MANAGEMENT, LLC	326,621	0	For
Aisling Capital Management LP	259,260	0	For
MOODY ALDRICH PARTNERS LLC	234,462	0	For
BlackRock	220,436	0	For
PNC BANK, NATIONAL ASSOCIATION	0	212,000	Against
Legg Mason	172,200	0	For
John Hancock	113,011	0	For
Manager Directed Portfolios	0	106,781	Against
Polar Asset Management Partners Inc.	96,500	0	For
Neuberger Berman	0	96,259	Against
Nationwide	76,547	0	For
ALPS ETF Trust	58,006	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

3. To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 603,137,815AGAINST: 195,320

VERONA PHARMA PLC’s own tally for this item (“Proposal 10. To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.”): 603,137,815 for, 195,320 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 93% for, 0.1% against (93% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,353,330 for, 0 against).

FOR 100%

FOR: 9,353,330 (100.0%)

Largest asset managers voting on “To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,243,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

4. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 618,024,719AGAINST: 65,608

VERONA PHARMA PLC’s own tally for this item (“Proposal 11. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024.”): 618,024,719 for, 65,608 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,353,330 for, 0 against).

FOR 100%

FOR: 9,353,330 (100.0%)

Largest asset managers voting on “To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,243,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

5. To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Section 561(1) of the Companies Act does not apply to any such allotment.

CAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.2% fund support · no official result

FOR 99.2%

The 34 asset managers below cast 99.2% of the shares they voted on this item FOR (9,283,545 for, 69,785 against).

FOR: 9,283,545 (99.3%)AGAINST: 69,785 (0.7%)

Largest asset managers voting on “To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
MUTUAL FUND SERIES TRUST	2,243,520	0	For
Fidelity	1,659,263	65,320	For
Vanguard	1,304,406	0	For
Federated Hermes	1,043,864	0	For
Prudential/PGIM	541,647	0	For
JANUS INVESTMENT FUND	492,127	0	For
American Century	487,463	0	For
Hartford	485,679	0	For
BlackRock	220,436	0	For
Legg Mason	172,200	0	For
John Hancock	113,011	0	For
Manager Directed Portfolios	106,781	0	For
Neuberger Berman	96,259	0	For
Nationwide	76,547	0	For
ALPS ETF Trust	58,006	0	For
Guardian Variable Products Trust	45,700	0	For
New York Life	34,260	0	For
CLEARWATER INVESTMENT TRUST	24,564	0	For
AIG/SunAmerica	18,734	0	For
Goldman Sachs	17,420	0	For
PENN SERIES FUNDS INC	16,749	0	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	0	For
BNY Mellon	5,300	0	For
ProShares	4,843	0	For
State Street	0	4,458	Against

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

6. To receive and approve the U.K. Directors' Remuneration Policy.

COMPENSATION

Combines 4 wordings of this item as funds reported it.

92% fund support · no official result

FOR 92%8%

The 34 asset managers below cast 92% of the shares they voted on this item FOR (8,586,146 for, 767,184 against).

FOR: 8,586,146 (91.8%)AGAINST: 767,184 (8.2%)

Largest asset managers voting on “To receive and approve the U.K. Directors' Remuneration Policy.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
MUTUAL FUND SERIES TRUST	2,243,520	0	For
Fidelity	1,724,583	0	For
Vanguard	1,304,406	0	For
Federated Hermes	1,043,864	0	For
Prudential/PGIM	0	541,647	Against
JANUS INVESTMENT FUND	492,127	0	For
American Century	487,463	0	For
Hartford	485,679	0	For
BlackRock	220,436	0	For
Legg Mason	172,200	0	For
John Hancock	113,011	0	For
Manager Directed Portfolios	0	106,781	Against
Neuberger Berman	0	96,259	Against
Nationwide	76,547	0	For
ALPS ETF Trust	58,006	0	For
Guardian Variable Products Trust	45,700	0	For
New York Life	34,260	0	For
CLEARWATER INVESTMENT TRUST	3,299	21,265	Against
AIG/SunAmerica	18,734	0	For
Goldman Sachs	17,420	0	For
PENN SERIES FUNDS INC	16,749	0	For
TRUST FOR PROFESSIONAL MANAGERS	8,014	1,232	For
BNY Mellon	5,300	0	For
ProShares	4,843	0	For
State Street	4,458	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

7. To re-elect Christina Ackermann as a director of the Company.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 617,786,657AGAINST: 169,976

VERONA PHARMA PLC’s own tally for this item (“Proposal 4. To re-elect Christina Ackerman as a Director of the Company.”): 617,786,657 for, 169,976 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,297,330 for, 0 against).

FOR 100%

FOR: 9,297,330 (100.0%)

Largest asset managers voting on “To re-elect Christina Ackermann as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,187,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

8. To re-elect Lisa Deschamps as a director of the Company.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 34 asset managers below cast 99.9% of the shares they voted on this item FOR (9,293,963 for, 3,367 against).

FOR: 9,293,963 (100.0%)AGAINST: 3,367 (0.0%)

Largest asset managers voting on “To re-elect Lisa Deschamps as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
MUTUAL FUND SERIES TRUST	2,187,520	0	For
Fidelity	1,724,583	0	For
Vanguard	1,304,406	0	For
Federated Hermes	1,043,864	0	For
Prudential/PGIM	541,647	0	For
JANUS INVESTMENT FUND	492,127	0	For
American Century	487,463	0	For
Hartford	485,679	0	For
BlackRock	220,436	0	For
Legg Mason	172,200	0	For
John Hancock	113,011	0	For
Manager Directed Portfolios	106,781	0	For
Neuberger Berman	96,259	0	For
Nationwide	76,547	0	For
ALPS ETF Trust	58,006	0	For
Guardian Variable Products Trust	45,700	0	For
New York Life	34,260	0	For
CLEARWATER INVESTMENT TRUST	21,265	3,299	For
AIG/SunAmerica	18,734	0	For
Goldman Sachs	17,420	0	For
PENN SERIES FUNDS INC	16,749	0	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	0	For
BNY Mellon	5,300	0	For
ProShares	4,843	0	For
State Street	4,458	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

9. To re-elect Martin Edwards as a director of the Company.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 617,654,873AGAINST: 309,040

VERONA PHARMA PLC’s own tally for this item (“Proposal 2. To re-elect Martin Edwards as a Director of the Company.”): 617,654,873 for, 309,040 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,297,330 for, 0 against).

FOR 100%

FOR: 9,297,330 (100.0%)

Largest asset managers voting on “To re-elect Martin Edwards as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,187,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

10. To re-elect Michael Austwick as a director of the Company.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 617,807,153AGAINST: 170,296

VERONA PHARMA PLC’s own tally for this item (“Proposal 5. To re-elect Michael Austwick as a Director of the Company.”): 617,807,153 for, 170,296 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,297,330 for, 0 against).

FOR 100%

FOR: 9,297,330 (100.0%)

Largest asset managers voting on “To re-elect Michael Austwick as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,187,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

11. To re-elect Sven Anders Ullman as a director of the Company.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 590,081,657AGAINST: 27,882,176

VERONA PHARMA PLC’s own tally for this item (“Proposal 3. To re-elect Sven Anders Ullman as a Director of the Company.”): 590,081,657 for, 27,882,176 against, per its Form 8-K filed 2024-04-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 647,372,062 outstanding shares: 91% for, 4% against (95% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,297,330 for, 0 against).

FOR 100%

FOR: 9,297,330 (100.0%)

Largest asset managers voting on “To re-elect Sven Anders Ullman as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,187,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

12. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended 31 December 2023.

CORPORATE GOVERNANCE

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 34 asset managers below cast 100% of the shares they voted on this item FOR (9,297,330 for, 0 against).

FOR: 9,297,330 (100.0%)

Largest asset managers voting on “To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended 31 December 2” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,187,520	For
Fidelity	1,724,583	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
Hartford	485,679	For
BlackRock	220,436	For
Legg Mason	172,200	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
ALPS ETF Trust	58,006	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

13. To approve an increase in the maximum aggregate level of NonExecutive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Companys Articles of Association to 750,000 per annum on an ongoing basis.

COMPENSATION

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 20 asset managers below cast 100% of the shares they voted on this item FOR (6,130,936 for, 0 against).

FOR: 6,130,936 (100.0%)

Largest asset managers voting on “To approve an increase in the maximum aggregate level of NonExecutive Director annual remuneration (by way of ” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,243,520	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
Hartford	485,679	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
Victory Capital	1,971	For
Blackstone Alternative Investment Funds	1,100	For
Principal	1,039	For
MML SERIES INVESTMENT FUND	671	For
Keel Point, LLC	310	For
MassMutual	185	For
Investment Managers Series Trust II	176	For

14. To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of 8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Companys existing ordinary share capital as at the close of business on March 13, 2024 (

CAPITAL STRUCTURE

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 20 asset managers below cast 100% of the shares they voted on this item FOR (6,130,936 for, 0 against).

FOR: 6,130,936 (100.0%)

Largest asset managers voting on “To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company o” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,243,520	For
Vanguard	1,304,406	For
Federated Hermes	1,043,864	For
Prudential/PGIM	541,647	For
Hartford	485,679	For
John Hancock	113,011	For
Manager Directed Portfolios	106,781	For
Neuberger Berman	96,259	For
Nationwide	76,547	For
Guardian Variable Products Trust	45,700	For
New York Life	34,260	For
CLEARWATER INVESTMENT TRUST	24,564	For
TRUST FOR PROFESSIONAL MANAGERS	9,246	For
Victory Capital	1,971	For
Blackstone Alternative Investment Funds	1,100	For
Principal	1,039	For
MML SERIES INVESTMENT FUND	671	For
Keel Point, LLC	310	For
MassMutual	185	For
Investment Managers Series Trust II	176	For

15. To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Company's Articles of Association to pounds750,000 per annum on an ongoing basis.

COMPENSATION

100% fund support · no official result

FOR 100%

The 14 asset managers below cast 100% of the shares they voted on this item FOR (3,222,394 for, 0 against).

FOR: 3,222,394 (100.0%)

Largest asset managers voting on “To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Vote
Fidelity	1,724,583	For
JANUS INVESTMENT FUND	492,127	For
American Century	487,463	For
BlackRock	220,436	For
Legg Mason	172,200	For
ALPS ETF Trust	58,006	For
AIG/SunAmerica	18,734	For
Goldman Sachs	17,420	For
PENN SERIES FUNDS INC	16,749	For
BNY Mellon	5,300	For
ProShares	4,843	For
State Street	4,458	For
Invesco	68	For
Aberdeen	7	For

16. To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Company's existing ordinary share capital as at the close of business on March 13,

CAPITAL STRUCTURE

98% fund support · no official result

FOR 98%

The 14 asset managers below cast 98% of the shares they voted on this item FOR (3,157,067 for, 65,327 against).

FOR: 3,157,067 (98.0%)AGAINST: 65,327 (2.0%)

Largest asset managers voting on “To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company o” at VERONA PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Fidelity	1,659,263	65,320	For
JANUS INVESTMENT FUND	492,127	0	For
American Century	487,463	0	For
BlackRock	220,436	0	For
Legg Mason	172,200	0	For
ALPS ETF Trust	58,006	0	For
AIG/SunAmerica	18,734	0	For
Goldman Sachs	17,420	0	For
PENN SERIES FUNDS INC	16,749	0	For
BNY Mellon	5,300	0	For
ProShares	4,843	0	For
State Street	4,458	0	For
Invesco	68	0	For
Aberdeen	0	7	Against

Largest VERONA PHARMA PLC shareholders voting in 2023-2024

Ranked by the number of VERONA PHARMA PLC shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 647,372,062 shares outstanding at the time of that meeting.

Top VERONA PHARMA PLC shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	RA CAPITAL MANAGEMENT, L.P.	0.96%
2	Fidelity	0.61%
3	Vivo Capital, LLC	0.56%
4	ORBIMED ADVISORS LLC	0.53%
5	Wellington	0.51%
6	Deep Track Capital, LP	0.49%
7	PERCEPTIVE ADVISORS LLC	0.45%
8	Carlyle Group Inc.	0.38%
9	MUTUAL FUND SERIES TRUST	0.35%
10	Federated Hermes	0.32%

Reported VERONA PHARMA PLC ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VERONA PHARMA PLC beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
RA Capital Management affiliates	9.27%	DEF14A
New Enterprise Associates affiliates	7.17%	DEF14A
Growth Equity Opportunities Fund IV, LLC	6.90%	13D
FMR LLC	6.06%	DEF14A
David Zaccardelli, Pharm.D.	1.96%	DEF14A
Mark W. Hahn	1.82%	DEF14A
BlackRock	0.59%	13F
Kathleen Rickard, M.D.	0.35%	DEF14A
Goldman Sachs	0.30%	13F
Morgan Stanley	0.24%	13F

Percentages above are of 647,372,062 shares outstanding, as reported by VERONA PHARMA PLC on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VERONA PHARMA PLC’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VERONA PHARMA PLC's shareholder meeting held 2024-04-26, in the 2023-2024 proxy season, 127 asset managers reported how they voted in their SEC Form N-PX filings, covering 980 separate fund positions. Their filings are grouped here into 16 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VERONA PHARMA PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-04-30.

VERONA PHARMA PLC proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.